Overexpression of matrix metalloproteinase-7 (MMP-7) correlates with tumor proliferation, and a poor prognosis in non-small cell lung cancer.

BACKGROUND Matrix metalloporteinase-7 (MMP-7) is a member of the MMP family, and it has been reported to play an important role in tumorigenesis, invasion and metastasis. We performed a retrospective study on the MMP-7 expression in non-small cell lung cancer (NSCLC) according to the clinical characteristics, biological markers and the Wnt1 expression. PATIENTS AND METHODS One hundred forty-seven postsurgical NSCLC patients were investigated. Immunohistochemistry was performed to evaluate the MMP-7 expression, the Ki-67 proliferation index, tumor angiogenesis and the Wnt1 expression. The TUNEL method was performed to investigate tumor apoptosis. RESULTS Seventy-six carcinomas (51.7%) were MMP-7-positive. The MMP-7 expression was significantly higher in squamous cell carcinomas than in adenocarcinomas (P<0.0001). The Ki-67 proliferation index was significantly higher in MMP-7-positvie tumors than in MMP-7-negative tumors (P=0.0003). However, there was no difference in the MMP-7 expression in relation to apoptosis or angiogenesis. Regarding its regulation, the MMP-7 expression significantly correlated with the Wnt1 expression (r=0.426, P<0.0001). The overall survival was significantly lower in patients with MMP-7-positive NSCLCs than in those with MMP-7-negative NSCLCs (P=0.0018). A Cox regression analyses also demonstrated MMP-7 status to be a significant prognostic factor (hazard ratio, 2.187; P=0.0023). CONCLUSIONS The overexpression of MMP-7 was associated with tumor proliferation, and a poor prognosis in NSCLCs. In addition, Wnt1 may play a critical role in regulating the intratumoral MMP-7 expression.

[1]  J. Neoptolemos,et al.  Comprehensive Analysis of Matrix Metalloproteinase and Tissue Inhibitor Expression in Pancreatic Cancer , 2004, Clinical Cancer Research.

[2]  E. Brambilla,et al.  Frequent loss of Fas expression and function in human lung tumours with overexpression of FasL in small cell lung carcinoma , 2003, The Journal of pathology.

[3]  K. Sugimachi,et al.  Matrix metalloproteinase-7 expression in gastric carcinoma. , 1996, Gut.

[4]  G. Evan,et al.  Wnt signaling promotes oncogenic transformation by inhibiting c-Myc–induced apoptosis , 2002, The Journal of cell biology.

[5]  Z. Werb,et al.  How matrix metalloproteinases regulate cell behavior. , 2001, Annual review of cell and developmental biology.

[6]  M. Mareel,et al.  Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1. , 2001, Journal of cell science.

[7]  A. Pozzi,et al.  Elevated matrix metalloprotease and angiostatin levels in integrin alpha 1 knockout mice cause reduced tumor vascularization. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[8]  Y. Okada,et al.  Contribution of matrilysin (MMP-7) to the metastatic pathway of human colorectal cancers , 1999, Gut.

[9]  Thomas Kirchner,et al.  β-Catenin Regulates the Expression of the Matrix Metalloproteinase-7 in Human Colorectal Cancer , 1999 .

[10]  J. Shrager,et al.  Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non-small cell lung carcinoma: long-term results and associations with pathologic response. , 2004, The Journal of thoracic and cardiovascular surgery.

[11]  M. Ueno,et al.  Wnt5a expression is associated with the tumor proliferation and the stromal vascular endothelial growth factor--an expression in non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  H. Yasumitsu,et al.  Purification and characterization of extracellular matrix-degrading metalloproteinase, matrin (pump-1), secreted from human rectal carcinoma cell line. , 1990, Cancer research.

[13]  T. Utsunomiya,et al.  Coexpression of Matrix Metalloproteinase-7 (MMP-7) and Epidermal Growth Factor (EGF) Receptor in Colorectal Cancer , 2004, Clinical Cancer Research.

[14]  T. Ishikawa,et al.  MMP-7 (matrilysin) accelerated growth of human umbilical vein endothelial cells. , 2002, Cancer letters.

[15]  Paul Polakis,et al.  The metalloproteinase matrilysin is a target of β-catenin transactivation in intestinal tumors , 1999, Oncogene.

[16]  H. Sasaki,et al.  Clinical significance of matrix metalloproteinase-7 and Ets-1 gene expression in patients with lung cancer. , 2001, The Journal of surgical research.

[17]  C. Mountain,et al.  Revisions in the International System for Staging Lung Cancer. , 1997, Chest.

[18]  M. Sugita,et al.  Mutations of the β- and γ-catenin genes are uncommon in human lung, breast, kidney, cervical and ovarian carcinomas , 2001, British Journal of Cancer.

[19]  Y. Nagashima,et al.  Expression of matrilysin in vascular endothelial cells adjacent to matrilysin‐producing tumors , 1997, International journal of cancer.

[20]  B. Fingleton,et al.  The metalloproteinase matrilysin proteolytically generates active soluble Fas ligand and potentiates epithelial cell apoptosis , 1999, Current Biology.

[21]  M. Kris,et al.  Long-term results of combined-modality therapy in resectable non-small-cell lung cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  J. Guillem,et al.  Matrix metalloproteinase-7 expression in colorectal cancer liver metastases: evidence for involvement of MMP-7 activation in human cancer metastases. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[23]  K. Okita,et al.  Increased expression of matrix metalloproteinase-7 in invasive early gastric cancer , 2003, Journal of Gastroenterology.

[24]  A. Brown,et al.  Induction of kidney epithelial morphogenesis by cells expressing Wnt-1. , 1994, Developmental biology.

[25]  Bengt Bergman,et al.  Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. , 2004, The New England journal of medicine.

[26]  H. Yamamoto,et al.  Association of matrilysin expression with recurrence and poor prognosis in human esophageal squamous cell carcinoma. , 1999, Cancer research.

[27]  R. J. Cersosimo.  Lung cancer: a review. , 2002, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[28]  W. Jiang,et al.  Matrilysin mediates extracellular cleavage of E-cadherin from prostate cancer cells: a key mechanism in hepatocyte growth factor/scatter factor-induced cell-cell dissociation and in vitro invasion. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[29]  B. Fingleton,et al.  Identification of novel matrix metalloproteinase-7 (matrilysin) cleavage sites in murine and human Fas ligand. , 2002, Archives of biochemistry and biophysics.

[30]  T. Dale,et al.  Signal transduction by the Wnt family of ligands. , 1998, The Biochemical journal.

[31]  G. Wick,et al.  Methods for the detection of apoptosis. , 1994, International archives of allergy and immunology.

[32]  Carlos López-Otín,et al.  Strategies for MMP inhibition in cancer: innovations for the post-trial era , 2002, Nature Reviews Cancer.

[33]  B. Hogan,et al.  Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[34]  S. Kuo,et al.  Expression spectra of matrix metalloproteinases in metastatic non-small cell lung cancer. , 2004, Oncology reports.

[35]  F. Hirahara,et al.  Expression of gelatinase A, tissue inhibitor of metalloproteinases-2, matrilysin, and trypsin(ogen) in lung neoplasms: an immunohistochemical study. , 1997, Human pathology.

[36]  I. Stamenkovic,et al.  CD44 anchors the assembly of matrilysin/MMP-7 with heparin-binding epidermal growth factor precursor and ErbB4 and regulates female reproductive organ remodeling. , 2002, Genes & development.

[37]  H. Clevers,et al.  Linking Colorectal Cancer to Wnt Signaling , 2000, Cell.

[38]  Constance E. Brinckerhoff,et al.  Matrix metalloproteinases: a tail of a frog that became a prince , 2002, Nature Reviews Molecular Cell Biology.

[39]  L. Matrisian,et al.  Matrilysin: an epithelial matrix metalloproteinase with potentially novel functions. , 1996, The international journal of biochemistry & cell biology.

[40]  M. Kurrer,et al.  APC mutations are infrequent but present in human lung cancer. , 2004, Cancer letters.

[41]  K. Sugimachi,et al.  Clinical significance of matrix metalloproteinase-7 expression in esophageal carcinoma. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[42]  B. Fingleton,et al.  Proliferative effects of apical, but not basal, matrix metalloproteinase-7 activity in polarized MDCK cells. , 2005, Experimental cell research.

[43]  B. C. Patterson,et al.  Angiostatin-converting Enzyme Activities of Human Matrilysin (MMP-7) and Gelatinase B/Type IV Collagenase (MMP-9)* , 1997, The Journal of Biological Chemistry.

[44]  A. Ben-Ze'ev,et al.  The Integration of Cell Adhesion with Gene Expression: The Role of β-Catenin , 2000 .

[45]  Zhimin Wei,et al.  Beta-catenin up-regulates the expression of cyclinD1, c-myc and MMP-7 in human pancreatic cancer: relationships with carcinogenesis and metastasis. , 2005, World journal of gastroenterology.

[46]  J. Woessner,et al.  Purification and properties of a small latent matrix metalloproteinase of the rat uterus. , 1988, The Journal of biological chemistry.